Sentinus LLC Reduces Position in Pfizer Inc. (NYSE:PFE)

Sentinus LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 25.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,710 shares of the biopharmaceutical company’s stock after selling 3,286 shares during the period. Sentinus LLC’s holdings in Pfizer were worth $258,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. boosted its stake in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 400 shares during the period. Beam Wealth Advisors Inc. boosted its stake in shares of Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after purchasing an additional 401 shares during the period. Finally, Providence Capital Advisors LLC boosted its stake in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after purchasing an additional 409 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 1.0%

NYSE:PFE opened at $22.83 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. The firm has a 50-day simple moving average of $23.65 and a 200-day simple moving average of $25.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the business posted $0.82 EPS. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

PFE has been the subject of several research reports. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.